FLUOCINOLONE ACETONIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H30F2O6
Molecular Weight	452.4891
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)O[C@]2([H])C[C@@]3([H])[C@]4([H])C[C@@]([H])(C5=CC(=O)C=C[C@]5(C)[C@]4([C@]([H])(C[C@]3(C)[C@]2(C(=O)CO)O1)O)F)F

InChI

InChIKey=FEBLZLNTKCEFIT-VSXGLTOVSA-N

InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H30F2O6
Molecular Weight	452.4891
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00591
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012787s071lblrev.pdf

Fluocinolone Acetonide is a corticosteroid that binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver. Fluocinolone Acetonide is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert). Preparations containing Fluocinolone Acetonide were first marketed under the name Synalar.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucocorticoid receptor 167 Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00591	Agonist 2470		2.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Corticosteroid-responsive dermatoses 16 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012787s071lblrev.pdf	Primary		Approved 8043	SYNALAR Approved Use SYNALAR® Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses. Launch Date -2.17123193E11
Chronic non-infectious uveitis affecting the posterior segment of the eye 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021737s000_PRNTLBL.pdf	Primary		Approved 8043	Retisert Approved Use Retisert is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Launch Date 1.11283195E12

C_max

Value	Dose	Co-administered	Analyte	Population
54 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1874579	0.8 mg single, topical dose: 0.8 mg route of administration: Topical experiment type: SINGLE co-administered:		FLUOCINOLONE ACETONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
354.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1874579	0.8 mg single, topical dose: 0.8 mg route of administration: Topical experiment type: SINGLE co-administered:		FLUOCINOLONE ACETONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
14.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1874579	0.8 mg single, topical dose: 0.8 mg route of administration: Topical experiment type: SINGLE co-administered:		FLUOCINOLONE ACETONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
6 ug 1 times / day multiple, intravitreal Highest studied dose Dose: 6 ug, 1 times / day Route: intravitreal Route: multiple Dose: 6 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15767049 Page: p.425	unhealthy, 24 –51 n = 6 Health Status: unhealthy Condition: Subfoveal choroidal neovascularization Age Group: 24 –51 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15767049 Page: p.425	Disc. AE: Central retinal vein occlusion... AEs leading to discontinuation/dose reduction: Central retinal vein occlusion (16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/15767049 Page: p.425
2 ug 1 times / day multiple, intravitreal Studied dose Dose: 2 ug, 1 times / day Route: intravitreal Route: multiple Dose: 2 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15921758 Page: p.1196	unhealthy, 43.2 n = 5 Health Status: unhealthy Condition: Posterior uveitis Age Group: 43.2 Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/15921758 Page: p.1196	Sources: https://pubmed.ncbi.nlm.nih.gov/15921758 Page: p.1196
0.6 ug 1 times / day multiple, intravitreal Recommended Dose: 0.6 ug, 1 times / day Route: intravitreal Route: multiple Dose: 0.6 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21813090 Page: p.1584	unhealthy n = 127 Health Status: unhealthy Condition: Diabetic macular edema Population Size: 127 Sources: https://pubmed.ncbi.nlm.nih.gov/21813090 Page: p.1584	Disc. AE: Increased intraocular pressure... AEs leading to discontinuation/dose reduction: Increased intraocular pressure (2.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/21813090 Page: p.1584
2 ug 1 times / day multiple, intravitreal Studied dose Dose: 2 ug, 1 times / day Route: intravitreal Route: multiple Dose: 2 ug, 1 times / day Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf Page: p.17, 18	unhealthy n = 168 Health Status: unhealthy Condition: Non-infectious uveitis Population Size: 168 Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf Page: p.17, 18	Other AEs: Intraocular pressure abnormal... Other AEs: Intraocular pressure abnormal Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf Page: p.17, 18

AEs

AE	Significance	Dose	Population
Central retinal vein occlusion	16.7% Disc. AE	6 ug 1 times / day multiple, intravitreal Highest studied dose Dose: 6 ug, 1 times / day Route: intravitreal Route: multiple Dose: 6 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15767049 Page: p.425	unhealthy, 24 –51 n = 6 Health Status: unhealthy Condition: Subfoveal choroidal neovascularization Age Group: 24 –51 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15767049 Page: p.425
Increased intraocular pressure	2.4% Disc. AE	0.6 ug 1 times / day multiple, intravitreal Recommended Dose: 0.6 ug, 1 times / day Route: intravitreal Route: multiple Dose: 0.6 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21813090 Page: p.1584	unhealthy n = 127 Health Status: unhealthy Condition: Diabetic macular edema Population Size: 127 Sources: https://pubmed.ncbi.nlm.nih.gov/21813090 Page: p.1584
Intraocular pressure abnormal		2 ug 1 times / day multiple, intravitreal Studied dose Dose: 2 ug, 1 times / day Route: intravitreal Route: multiple Dose: 2 ug, 1 times / day Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf Page: p.17, 18	unhealthy n = 168 Health Status: unhealthy Condition: Non-infectious uveitis Population Size: 168 Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf Page: p.17, 18

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601 inhibitor 1467 inducer 707	inhibitor 1604	inhibitor 1702

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1383 CYP2A6 627 CYP2C19 1325 CYP2E1 790	P-gp 1400

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1532	inhibitor 3045 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 659	inhibitor 3045 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 1392	inhibitor 3045 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 1648	inhibitor 3045 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2D6 1738	inhibitor 3045 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTg5In19	no [IC50 >10 uM]
CYP2E1 871	inhibitor 3045 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP3A4 1772	inhibitor 3045 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTg5In19	no [IC50 >10 uM]
CYP3A4 1772	inducer 1440 Sources: https://go.drugbank.com/drugs/DB00591 \| https://pubmed.ncbi.nlm.nih.gov/23143891/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1601	substrate 3113 Sources: https://go.drugbank.com/drugs/DB00591 \| https://pubmed.ncbi.nlm.nih.gov/23143891/ \| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C29055&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null	yes
P-gp 1400	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/11724763/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31623	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31623
ChemicalBook	CB6394372	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6394372
MolPort	MolPort-002-528-328	https://www.molport.com/shop/molecule-link/MolPort-002-528-328
Selleck Chemicals	Fluocinolone-acetonide(Flucort-N)	http://www.selleckchem.com/products/Fluocinolone-acetonide(Flucort-N).html
ZINC	ZINC000003977981	http://zinc15.docking.org/substances/ZINC000003977981
eMolecules	30069661	https://www.emolecules.com/cgi-bin/more?vid=30069661
eMolecules	36516846	https://www.emolecules.com/cgi-bin/more?vid=36516846
eMolecules	538508	https://www.emolecules.com/cgi-bin/more?vid=538508

PubMed

Title	Date	PubMed
Asthma steroid pharmacogenetics: a study strategy to identify replicated treatment responses.	2004	16113459
Fluocinolone acetonide topical oil for scalp psoriasis.	2004 Dec	15764047
Improved quality of life with effective treatment of facial melasma: the pigment trial.	2004 Jul-Aug	15303781
Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period.	2004 Jun	15279731
Flunisolide HFA for the treatment of asthma: an old friend reformulated.	2004 May	15155115
Treatment with inhaled flunisolide.	2004 May	15136418
In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics.	2004 Sep	15291899
Utilizing combination therapy to optimize melasma outcomes.	2004 Sep-Oct	15552597
Fluocinolone acetonide ophthalmic--Bausch & Lomb: fluocinolone acetonide Envision TD implant.	2005	15777105
Comparison of the analysis of corticosteroids using different techniques.	2005 Jan	15700162
Effects of drug treatment on inflammation and hyperreactivity of airways and on immune variables in cats with experimentally induced asthma.	2005 Jul	16111148
The nitrosterols--a step forward from the steroid anti-inflammatory drugs?	2005 Jul	16022571
Photochemistry and phototoxicity of fluocinolone 16,17-acetonide.	2005 Mar-Apr	15535735
Retisert (Bausch & Lomb/Control Delivery Systems).	2005 Nov	16312138
Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide.	2005 Nov	16275364
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.	2005 Sep-Oct	16167418
Flunisolide decreases exhaled nitric oxide and nitrotyrosine levels in asthmatic children.	2006	17047290
A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream.	2006	16901182
Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease.	2006	16293958
Once-daily intranasal corticosteroids for allergic rhinitis. Examining Treatment issues.	2006 Apr	16972477
Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.	2006 Apr	16488337
Postinflammatory hyperpigmentation: evolving combination treatment strategies.	2006 Aug	16977792
Long-term release of fluocinolone acetonide using biodegradable fumarate-based polymers.	2006 Aug 28	16872709
[New drugs in the treatment of noninfectious uveitis].	2006 Dec	17199159
Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy.	2006 Dec	17176300
Ethnic considerations in the treatment of Hispanic and Latin-American patients with hyperpigmentation.	2006 Dec	17176299
Intravitreal steroids in the management of macular oedema.	2006 Dec	17083528
Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats.	2006 Jan-Feb	16496924
Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.	2006 Jul	16832025
Dark brown scaly plaques on face and ears.	2006 Jun	16750067
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.	2006 Jun	16690128
Community-based trial of a triple-combination agent for the treatment of facial melasma.	2006 Mar	16610738
Expression of TNF-alpha in oral lichen planus treated with fluocinolone acetonide 0.1%.	2006 Mar	16454812
Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion.	2006 Oct	17050954
Topical glucocorticosteroids in rhinitis: clinical aspects.	2006 Oct	16923704
Nebulized drug admixtures: effect on aerosol characteristics and albuterol output.	2006 Winter	17196077
Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management.	2007	17722513
Pharmacotherapies for diabetic retinopathy: present and future.	2007	17713597
Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.	2007	17628122
Hypertrichosis as a side effect of inhaled steroids in children.	2007 Apr	17351929
Epithelial cells in the hair follicle bulge do not contribute to epidermal regeneration after glucocorticoid-induced cutaneous atrophy.	2007 Dec	17657244
Injectable, in situ forming poly(propylene fumarate)-based ocular drug delivery systems.	2007 Dec 1	17514745
Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma.	2007 Feb	17373174
Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant.	2007 Feb	17258523
Strength and endurance of the respiratory and handgrip muscles after the use of flunisolide in normal subjects.	2007 Jul	17509852
Compressor/nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency).	2007 Jul-Aug	17876957
Vitreous band formation and the sustained-release, intravitreal fluocinolone (Retisert) implant.	2007 Jun	17562999
A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.	2007 Mar	17348994
Retisert: is the new advance in treatment of uveitis a good one?	2007 Mar	17341531
Drug delivery methods for posterior segment disease.	2007 May	17435432

Patents

Sample Use Guides

In Vivo Use Guide

generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

Route of Administration: Topical

In Vitro Use Guide

Fluocinolone Acetonide (10(−6) M) inhibited the expression of inflammatory cytokines and matrix metalloproteinases in murine immortalized keratinocytes

Substance Class	Chemical Created by `admin` on `Fri Jun 25 20:53:42 UTC 2021` Edited by `admin` on `Fri Jun 25 20:53:42 UTC 2021`
Record UNII	0CD5FD6S2M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FLUOCINOLONE ACETONIDE

Official Name

English

FLUOCINOLONE ACETONIDE COMPONENT OF NEO-SYNALAR

Common Name

English

TRI-LUMA COMPONENT FLUOCINOLONE ACETONIDE

Common Name

English

ILUVIEN COMPONENT FLUOCINOLONE ACETONIDE

Brand Name

English

FLUOCINOLONE ACETONIDE [INN]

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 6,9-DIFLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (6.ALPHA.,11.BETA.,16.ALPHA.)-

Common Name

English

DERMOTIC

Brand Name

English

FLUOCINOLIDE (ACETATE)

Common Name

English

OTO-SYNALAR

Brand Name

English

FLUOCINOLONE ACETONIDE [WHO-DD]

Common Name

English

FLUOCINOLONE ACETONIDE [MART.]

Common Name

English

ILUVIEN

Brand Name

English

FLUOCINOLONE ACETONIDE [USAN]

Common Name

English

FLUOCINOLONE ACETONIDE [USP]

Common Name

English

SYNALAR

Brand Name

English

FLUOCINOLONE ACETONIDE COMPONENT OF ILUVIEN

Brand Name

English

DERMA-SMOOTHE/FS

Brand Name

English

FLUOCET

Brand Name

English

FLUOCINOLONE ACETONIDE [EP MONOGRAPH]

Common Name

English

FLUOCINOLONE ACETONIDE [HSDB]

Common Name

English

6.ALPHA.,9-DIFLUORO-11.BETA.,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE, CYCLIC 16,17-ACETAL WITH ACETONE

Common Name

English

FLUOCINOLONE ACETONIDE [GREEN BOOK]

Common Name

English

FLUOCINOLONE ACETONIDE [MI]

Common Name

English

FLUOCINOLONE ACETONIDE [ORANGE BOOK]

Common Name

English

FLUONID

Brand Name

English

FLUOCINOLONE ACETONIDE [VANDF]

Common Name

English

FLUOCINOLONE ACETONIDE [USP-RS]

Common Name

English

FLUOCINOLONE ACETONIDE [JAN]

Common Name

English

YUTIQ

Brand Name

English

RETISERT

Brand Name

English

OTOVEL COMPONENT OF FLUOCINOLONE ACETONIDE

Common Name

English

FLUOCINOLONE ACETONIDE COMPONENT OF TRI-LUMA

Common Name

English

OTOVEL COMPONENT FLUOCINOLONE ACETONIDE

Brand Name

English

FLUOCINOLONE ACETONIDE COMPONENT OF OTOVEL

Common Name

English

NSC-92339

Code

English

FS SHAMPOO

Brand Name

English

NEO-SYNALAR COMPONENT FLUOCINOLONE ACETONIDE

Common Name

English

FLUCINOLONE ACETONIDE

Common Name

English

FLUOCINOLONE ACETONIDE [USP MONOGRAPH]

Common Name

English

CAPEX

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QS02CA05